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The aim of this study was to conduct a cost-utility study of adefovir, entecavir, interferon
alpha,  pegylated interferon alpha, lamivudine and tenofovir for chronic hepatitis B in the
context  of Brazilian Public Health Care System. A systematic review was carried out for
efﬁcacy  and safety. Another review was performed to collect utility data and transition prob-
abilities between health states. A Markov model was developed in a time horizon of 40 years
with  annual cycles for three groups of: HBeAg positive, HBeAg negative, and all patients.
These  strategies were compared to a fourth group that received no treatment. Discount
rates  of 5% were applied and sensitivity analyses were performed. Tenofovir offered the best
cost-utility ratio for the three evaluated models: U$397, U$385 and U$384 (per QALY, respec-
tively,  for HBeAg positive, negative, and all patients). All other strategies were completely
dominated  because they showed higher costs and lower effectiveness than tenofovir. The
sequence of cost-utility in the three models was: tenofovir, entecavir, lamivudine, adefovir,
telbivudine,  pegylated interferon alpha, and interferon alpha. In the sensitivity analysis,
adefovir  showed lower cost-utility than telbivudine in some situations. The study has some
limitations, primarily related to the creation of scenarios and modeling. In this study, teno-fovir  presented the best cost-utility ratio. The results obtained in this study will be valuable
in  decision-making and in the review of the clinical protocol, mainly involving the allocation
of  available resources for health care.
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
More  than two billion people alive today have been infected
with  hepatitis B virus, and about 350 million remain infected.
It  is estimated that chronic hepatitis B is among the ten leading
causes  of death worldwide. Individuals with chronic hepatitis
B  have an increased risk of developing liver cirrhosis and hepa-
tocellular  carcinoma, causing the death of one million patients
annually.1–3
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Este é um artigo Open Access sob a licençaTreatments of chronic hepatitis B aim to prevent or reduce
the  risk of liver cirrhosis and hepatocellular carcinoma. They
also  improve viral suppression, and seek to normalize ALT lev-
els, decrease liver damage, and seroconversion of HBeAg (in
HBeAg  positive patients).1,3
Some of the pharmacological options for treating chronic
hepatitis B include: interferon alpha (IFN-), pegylated (PEG-o Lothário Meissner, 632, Jardim Botânico, Curitiba, PR, Brazil.
IFN-)  and nucleoside/nucleotide analogs: lamivudine (LAM),
entecavir  (ETV), adefovir dipivoxil (ADF), telbivudine (LDT),
and  tenofovir disoproxil fumarate (TDF).
 de CC BY-NC-ND
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IFN-alpha is administered subcutaneously. It acts through
wo  mechanisms in chronic hepatitis B: (i) antiviral action with
irect  inhibition of viral DNA synthesis; and (ii) immunomod-
latory action. The nucleoside/nucleotide analogs are used
rally  and inhibit reverse transcription during the viral repli-
ation  cycle in the hepatocyte.3
The incorporation of health technologies involves the
ntroduction of new equipment, health products, and drugs.
n  general, new technology is expensive, bringing about the
uestion  of whether the improvement in results is signif-
cant  vis-à-vis the aggregate cost of the new therapy. The
ntroduction of economic evaluation methods applied to clin-
cal  decision making has been driven by the emergence of
ew  drugs, the rise in pharmaceutical spending, the vari-
bility  and uncertainty in clinical practice. Additionally, there
s  a need to prioritize the use of drugs aimed at improv-
ng  quality of life of patients, contributed in the selection
mong pharmacological alternatives to be used in the health
ystem.  Economic evaluations in health care offer the possi-
ility  for a more  rational use of drugs and better allocation of
vailable  resources; that is, they help determine how much
ore  is needed to invest in a technology for an additional
eneﬁt.
The  effectiveness and cost of treatments may  differ in
arying  proportions. If the cost-effectiveness of each treat-
ent  is clearly analyzed, the proper allocation of resources
ecomes easier. The aim of this study was  to conduct a
ost-utility analysis of existing drugs for the treatment of
hronic  hepatitis B in the context of the Brazilian public health
ystem.
aterials  and  methods
tudy  design
he target population of this study was  selected from a sys-
ematic  review. It is composed of male and female adult
atients with no history of resistance to antiviral drugs, and
ithout  coinfection with HIV, hepatitis C or hepatitis D virus.
atients  were  also tested for cirrhosis or hepatocellular carci-
oma  at the beginning of treatment.
The technologies evaluated in this study were  the drugs for
hronic  hepatitis B in the usual doses used in Brazil, according
o  the clinical guideline:
 Adefovir dipivoxil: 10 mg per day orally.
 Entecavir: 0.5 mg  per day orally.
 Interferon-: 5 MUI  daily.
 Pegylated interferon-: 1.5 mcg/kg of pegylated interferon
alpha 2b subcutaneously administered weekly (used as ref-
erence  patients weighing 60 kg).
 Lamivudine: 100 mg  per day orally.
 Telbivudine: 600 mg  per day orally.
 Tenofovir disoproxil fumarate: 300 mg  per day orally.Patients receiving these drugs were  compared to those
eceiving no treatment.
We  considered patients with chronic hepatitis B who were
ollowed  up clinically, but did not receive treatment.3;1 7(4):418–426  419
Clinical  data  search
A systematic review was  performed for published articles that
evaluate  the efﬁcacy and safety of treatments for chronic
hepatitis B. It was conducted in ﬁve baselines: Cochrane
Library, MedLine/PubMed, LILACS, SCIELO, and IPA (Inter-
national  Pharmaceutical Abstracts). We considered studies
published  in Portuguese, English, German or Spanish, pub-
lished  between 2000 and July 2011.
Two independent reviewers extracted data and assessed
the  trial’s quality using the Jadad scale.4 Only studies of
medium  and high quality (at least 3 points on the Jadad scale)
were  included. Inclusion criteria were randomized controlled
trials  (RCTs) lasting for at least three months. We  excluded
review papers and editorials, case studies or studies with
fewer  than 10 patients.
Eligible  studies were those conducted on adult patients
older than 18 years, who had been diagnosed with chronic
hepatitis B, received one of the drugs evaluated in the usual
doses,  and were  compared with patients receiving other drugs,
the  association of two drugs, or a placebo. Studies, where the
control  group was  given the same drug but in different doses
or  for a different duration of therapy, were excluded. In case
of  discrepancy in any of the enumerated steps, the discordant
results  were resolved by consensus between the reviewers
and,  when necessary, by a third reviewer.
From the selected articles, extracted data included:
viral response, lack of response to treatment, treatment
withdrawals, viral resistance, HBeAg seroconversion, viral
breakthrough, and adverse events. Data were extracted on
pre-prepared  tables and separated into three groups: HBeAg
positive  patients, HBeAg negative patients, and a third group
comprising  all patients. This third group was created because
some  articles presented the aggregate results of HBeAg posi-
tive  and negative patients.
Data  about  utility  and  transition  probabilities  between
health  states
Another systematic review was  conducted looking for stud-
ies  that assessed the utility of patients with chronic hepatitis
B  in each condition. The transition probabilities of patients
between health states were also extracted from these studies.
This  search was made in PubMed/MedLine. We  also looked at
studies that evaluated quality of life of patients at different
stages  of chronic hepatitis B, evaluated by a generic quality of
life  questionnaire.
Modeling
The TreeAge Pro® software was  used to construct a decision-
analytical Markov model with estimates of the natural history
of  chronic hepatitis B infection. Scenarios were  created assum-
ing  health conditions and situations arising from the use of
drugs  and also from clinical pathology. The scenarios consid-
ered  that the sequence of events that might occur would be
the  same for all interventions, carrying only the probability of
events  occurring in different treatments and also their costs
and  utilities.
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The model was  ﬁrst applied to patients already diagnosed
with  chronic hepatitis B infection. The decision node repre-
sents  the patient’s treatment options (ADF, ETV, IFN-, LAM,
TDF,  LdT and PEG-IFN-) or no treatment. The treatment
was  considered discontinued in the states, “serious adverse
events”  or “death”. Furthermore, it was  considered that in
the  states, “no response to treatment” and “viral resistance,”
the  treatment was  changed to TDF, as recommended by the
Brazilian  Guideline (for patients who  received TDF, this was
changed  to ETV).
For  the state, “death,” mortality data from the Brazilian
general population was  used, considering patients aged 40
years  in whom mean disease onset was  found in the system-
atic  review.
After building the model, the yearly costs of each stage
were  added. The data were extrapolated to a time horizon
of  40 years, considering the chronic nature of the disease.
We  performed a cost-utility analysis, which measures the
cost  of treatment related to QALY.5 The incremental cost-
effectiveness ratio (ICER) was  evaluated to compare the
alternatives that were  more  expensive and more  effective than
others.
Costs
To evaluate the cost of each treatment, the parameters of
the  Brazilian public health system were used; only direct
costs  were  included. The cost of the drugs were obtained by
averaging  the amounts paid by the Ministry of Health in the
bids  made during the year 2011, with the exception of the LdT,
which  is not funded by the Brazilian public health system.
For  this product, the ABC Pharma table was used, which
standardizes the selling price of medicines in the private
network in the country. For the cost of other procedures (con-
sultations,  examinations, hospitalizations and surgeries), we
used the cost table produced by the Brazilian health system
hospitals.
Discount  rate
The discount rate used in the study was  5%, both for cost and
effectiveness values.
Sensitivity  analysis
The uncertainties were  minimized with sensitivity analyses
that  were  performed using univariate analysis, varying the
parameters  of cost and effectiveness for more  and less. To
evaluate  the robustness of the method and reduce uncertain-
ties,  the following types of analyses were performed:
- Change the weight of the patients using PEG-IFN- 2b from
60  to 70 kg; ranged the utilities of treatment as reported in
the  literature.
-  Variation of the cost of each treatment according to the max-
imum  and minimum prices paid for each drug in the tenders
held  during 2011.
-  Discount rates varied between 0 and 10%.
- Transition probabilities between health states were varied
from  minimum and maximum values found in literature. 1 3;1  7(4):418–426
Results
Systematic  review  of  clinical  data
In the ﬁrst stage of the systematic review, 1174 articles
published between 2000 and July 2011 were  found in the
databases. Of these, 100 randomized clinical trials were
selected  based on their abstracts. Of these, 246–29 studies met
the  inclusion criteria and were  included.
We included data only from studies that evaluated the
patients during one year. The extracted probabilities were
described  in Table 1 for HBeAg positive, negative, and all
patients.  For HBeAg negative patients, we found no RCTs that
evaluated  the IFN- alone, without association, and met
the  inclusion criteria. Therefore, for this group of patients,
the  drug was not evaluated.
Utilities
31 articles were  found in the systematic review performed
to  search for the utilities of patients with chronic hepatitis
B  in different health states. Of these, only three articles met
the  inclusion criteria and were original, while in the other
28  papers the utilities were taken from another study. Of the
three  resulting articles, the study by Levy et al.30 was  chosen
for  the extraction of utility values, because it was  a multi-
center  study conducted on 1134 patients, on whom the Health
Related  Quality of Life Questionnaire (HRQOL) was  conducted.
The  utility values found for each state of health were  (range):
-  Uncomplicated chronic hepatitis B: 0.68 (from 0.66 to 0.70).
-  Compensated cirrhosis: 0.69 (0.66–0.71).
- Decompensated cirrhosis: 0.35 (0.32–0.37).
- Hepatocellular carcinoma: 0.38 (0.36–0.41).
- Liver transplantation (ﬁrst year): 0.57 (0.54–0.60).
- Liver transplantation (other years): 0.67 (0.64–0.69).
Some utility values were not found in the literature and
therefore were  adapted from the selected study. For the out-
comes  “viral response” and “HBeAg seroconversion”, values
were  considered equivalent to the value “health”. The out-
comes  “no response to treatment,” “withdrawal due to adverse
events,”  and “viral resistance” were  considered equivalent to
the value “uncomplicated chronic hepatitis B”.
Transition  probabilities
The transition probabilities between the health states of
chronic  hepatitis B were also extracted from the studies
selected in the systematic review,2,31–37 obtaining the average,
maximum and minimum values. The values are described in
Table  2.
In  untreated patients the following probabilities were
considered:33,38
• Compensated cirrhosis: 23.89%.
• Clinical remission: 1.6%.
•  Death: 2.9%.
•  Hepatocellular carcinoma: 1.5%.
• Hepatocellular carcinoma to death: 50%.
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Table 1 – Probabilities of patients reaching each health state, starting from the state “chronic hepatitis B” for each of the
treatments.
Drug Viral
responsea
HBeAg sero-
conversion
Viral
breakthrough
Viral
resistance
Withdrawals due to
adverse events
No response
HBeAg positive patients
ADF9,10,26 0.2175 0.1127 0.0909 0.0186 0.0150 NR
ETV7–9 0.6589 0.2041 0.0169 NR 0.0026 0.0537
IFN-11,13 0.1756 0.1646 0.0625 NR 0.0405 NR
PEG-IFN-12,16 0.1820 0.2433 NR NR 0.0364 NR
LAM11,16 0.3741 0.1979 0.1655  0.1188 0.0302 0.1186
LdT18,19,26 0.6154 0.2262 0.0631  0.0569 0.0000 0.0463
TDF10 0.8312 0.2092 0.0235 NR 0.0000 NR
HBeAg negative patients
ADF10,17,20,26 0.5917 – 0.0909 0.0186 0.0081 NR
ETV22 0.9015 – 0.0169 NR 0.0185 0.0537
IFN- NR – NR NR NR NR
PEG-IFN-10,21,24 0.6407 – NR NR 0.0606 NR
LAM10,18,23,24 0.7312 – 0.1224 0.1061 0.0465 0.0268
LdT18,19,26 0.8802 – 0.0225 0.0225 0.000 0.0045
TDF10 0.9320 – 0.0235 NR 0.0200 NR
All patients
ADF9,10,17,20,25,26 0.3748 0.1127 0.0909 0.0186 0.0132 NR
ETV7–9,22 0.7697 0.1909 0.0169 NR 0.0132 0.0537
IFN-11,13 0.1756 0.1646 0.0625 NR 0.0405 NR
PEG-IFN-10,12,16,21,24 0.3227 0.2433 NR NR 0.0438 NR
LAM6,10–16,18,23,24 0.5140 0.1979 0.1567 0.1152 0.0241 0.1013
LdT18,19,26 0.6872 0.2262 0.0528 0.0482 0.0000 0.0351
TDF10 0.8592 0.2092 0.0235 NR 0.0117 NR
ADF, adefovir dipivoxil; ETV, entecavir; IFN-, interferon alpha; PEG-IFN-, pegylated interferon alpha; LAM, lamivudine; LdT, telbivudine; TDF,
tenofovir disoproxil fumarate; NR, not related.
a HBV DNA reduction to indetectable values.
Table 2 – Probabilities of transition between the health status of chronic hepatitis B extracted from the studies of the
systematic review.
Initial state Final state Probability (range) References
Chronic hepatitis B Compensated cirrhosis 0.0488 (0.02–0.09) 28,30–33
Hepatocellular carcinoma 0.0115 (0.008–0.015) 9,28–33
Death 0.0014 2
HBeAg seroconversion 0.0160 32
Viral resistance Death 0.0290 28
Seroconversion Compensated cirrhosis 0.0391 28
Hepatocellular carcinoma 0.0030 9,30
Compensated cirrhosis Decompensated cirrhosis 0.0572 (0.031–0.099) 28–33
Hepatocellular carcinoma 0.0391 (0.02–0.071) 29–33
Death 0.0500 (0.049–0.051) 28,29,32
Hepatocellular carcinoma Liver  transplantation 0.0008 32
Death 0.3173 (0.233–0.433) 29,33
Decompensated cirrhosis Hepatocellular carcinoma 0.0652 (0.022–0.034) 30–33
Liver transplantation 0.0260 (0.014–0.05) 30–33
Death 0.2506 (0.144–0.39) 29–33
Liver transplantation Death 0.1098  (0.069–0.15) ﬁrst year 30,31
0.0217 (0.015–0.025) following years 30,31
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Table 3 – Drugs annual cost.
Drug Annual
doses
Average  cost
per dose (U$)
Minimum
cost per dose
(U$)
Maximum
cost per dose
(U$)
Average annual
cost (U$)
Annual
minimum
cost (U$)
Annual
maximum
cost (U$)
ADF 10 mg 365 3.41 3.13 3.92 1246 1142 1432
ETV 0.5 mg 365 5.06 4.91 5.30 1266 1791 1933
IFN- 2B 5000 UI 156 20.55 20.55 20.55 3206 3206 3206
LAM 365 0.32 0.32 0.32 117 117 117
PEG-IFN- 2b 100 mcg 52a 220.93 220.93 220.94 11,488 11,488 11,489
LdT 365 13.63 11.31b 15.95b 4976 4130 5823
tient TDF 365 2.09 1.74 
a Was considered pegylated interferon- 2B 1.5 mcg/kg for a 60 kg pa
Treatment  costs
Costs of drugs per patient over a one year treatment period are
shown in Table 3. We  calculated the average cost of each drug
in  the year 2011, considering that the price can vary between
the  bids. The cost of IFN- and PEG-IFN- was  added in the
Markov  model only for the ﬁrst year because Brazilian guide-
lines  prohibit therapy with interferon beyond one year.
Costs  of  health  states
For the cost of health states deﬁned by decompensated cirrho-
sis,  hepatocellular carcinoma and liver transplantation, values
were  taken from another study conducted in Brazil in 2005, for
which the price list has not been updated since then:39
- Decompensated cirrhosis: U$ 12,803.
- Hepatocellular carcinoma: U$ 2770. This cost does not take
into  consideration chemotherapy.
-  Liver transplantation: U$ 50,798 in the ﬁrst year and subse-
quent  years we used the cost of clinical care.Modeling
Three Markov models were  developed: for HBeAg positive,
negative, and for all patients (Fig. 1). The main difference in
Withdr
Hepat
Viral re
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Compe
Death
Viral res
HBeAg 
Chronic hepatitis B Drug A Treatment
1
Viral response
Death
Death
No response
Fig. 1 – Markov model used 2.34 763 634 853
(dose = 90 mcg).
the  model of HBeAg negative patients is that there is no sero-
conversion  of HBeAg.
It  was  considered that all patients started in the state
“treatment” and then transited to one of the health states:
viral  response, death, no response to treatment, withdrawal
due  to adverse events, seroconversion of HBeAg (in HBeAg
positive  patients), viral resistance, compensated cirrhosis, or
hepatocellular carcinoma.
Cost-utility  analyses
The results of cost-utility analyses are shown in Fig. 2, for
HBeAg  positive, negative and all patients, respectively. The
costs,  effects, and cost-utility are described in Table 4. The
results  are in increasing order of cost-utility values, and com-
pared  to the item “no treatment”.
Sensitivity  analysis
By varying the initial utility or utility of the state viral response
in  HBeAg negative patients, in some cases, PEG-IFN becomes
less  cost-effective than the option “no treatment”. Varying the
cost  of LdT in HBeAg negative patients, LdT shows better cost-
utility  values than ADF. In the three groups of patients, varying
the  discount rate to 10%, LAM was  more  cost-utility than ETV.
awal due to AE
Withdrawal due to AE
ocarcinom
Hepatocarcinom
sistence
Viral resistence
ent
Treatment
Treatment Treatment
nsated cirrhosis
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seroconversion
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Death
Death
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Hepatocarcinom
Descompensated cirrhosis Descompensated cirrhosis
for cost-utility analysis.
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Cost-effectiveness analysis in
HBeAg positive patients
Cost-effectiveness analysis in
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Cost-effectiveness analysis in HBeAg
positive and negative patients
PEGIFN-alpha
Tenofovir
IFN-alpha
Entecavir
Adefovir
No treatment
Lamivudine
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Co
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 (R
$)
Effectiveness (QALY)
Fig. 2 – Cost-utility of treatments in HBeAg positive, HBeAg negative and all patients. PEG-IFN, pegylated interferon-; IFN,
interferon-; QALY, quality adjusted life years.
d
d
o
a
v
t
t
dBecause TDF had the best cost-utility of the evaluated
rugs, the worst scenario was  created for TDF based on
ata  from systematic reviews. The probability of devel-
ping  hepatocellular carcinoma, compensated cirrhosis,
nd  decompensated cirrhosis was  ranged to the highest
alue  found in the literature. Still, TDF was the alterna-
ive  with the better cost-effectiveness ratio among the
hree  groups of evaluated patients; all other strategies were
ominated.
Table 4 – Cost-utility results in ascending order of cost-utility ra
Drug Cost (U$) Incremental
cost  (U$)
Effect  (QA
HBeAg positive patients
TDF  4721 −14,293 11.87
ETV 6399 −12,615 11.80 
LAM 6723 −12,291 10.37 
ADF 11,775 −7239 11.06 
LdT 15,796 −3218 11.50 
No treatment 19,014 – 7.74 
PEG-IFN- 41,906 22,892 11.34 
IFN- 42,534 23,520 11.10 
HBeAg negative patients
TDF  4592 −14,471 11.92 
ETV 5509 −13,554 11.91 
LAM 5653 −13,410 10.92 
ADF 7894 −11,169 11.50 
LdT 8933 −10,130 11.88 
PEG-IFN- 15,218 −3845 11.81 
No treatment 19,063 – 7.74 
All patients
TDF 4664 −14,399 11.85 
ETV 5896 −13,167 11.83 
LAM 5919 −13,144 10.75 
ADF 9511 −9552 11.16 
LdT 13,639 −5424 11.58 
No treatment 19,063 – 7.74 
PEG-IFN- 28,817 9754 11.54 
IFN- 42,141 23,078 11.01 
PEG-IFN-, pegylated interferon-alpha; IFN-, interferon-alpha; QALY, quaDiscussion
The cost-utility of TDF for the treatment of chronic hepatitis
B  was  higher than for the other drugs in all groups of patients
(HBeAg  positive, negative and total). All other strategies were
dominated,  that is, all other treatment strategies had higher
cost  and lower effect than TDF. ETV was the second most cost-
effective  drug in all groups. In the three groups studied, the
tio.
LY) Incremental
effect  (QALY)
Cost-utility
(U$/QALY)
Incremental
cost-utility
4.13 397
4.06 542 Dominated
2.63 648 Dominated
3.32 1064 Dominated
3.76 1371 Dominated
– 2456 Dominated
3.60 3695 Dominated
3.36 3832 Dominated
4.18 385
4.17 462 Dominated
3.19 518 Dominated
3.77 686 Dominated
4.14 752 Dominated
4.07 1289 Dominated
– 2463 Dominated
4.11 394
4.09 498 Dominated
3.01 551 Dominated
3.43 852 Dominated
3.84 1178 Dominated
– 2463 Dominated
3.80 2497 Dominated
3.27 3827 Dominated
lity adjusted life years.
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TDF and ETV QALY values were very close. However, due to
the  lower cost of TDF, its cost-effectiveness ratio was  better
when  compared to ETV.
IFN- was  the strategy with the worst cost-effectiveness
ratio in HBeAg positive patients and the group comprising all
patients,  and also was  less cost-effective than the no treat-
ment  option. Moreover, its use in HBeAg positive patients
should be evaluated, especially in the presence of cirrhosis.
In  this case, treatment with IFN- can lead to serious com-
plications such as neutropenia, sepsis and hemorrhages.40
Further, this treatment leads to a high proportion of adverse
events  (about 4%) and showed lowest rates of viral response
(Table  1). Patients without viral load reduction and/or HBeAg
seroconversion are more  likely to develop liver cirrhosis and
hepatocellular  carcinoma, which is associated with higher
costs  in treatment.41
Among the other treatment options, PEG-IFN had the
worst  cost-utility ratio in HBeAg negative patients. In the
other  two groups, PEG-IFN was  only better than IFN. However,
PEG-IFN- appears to have some important advantages when
compared  to nucleosides/nucleotides analogs, because it does
not lead to viral resistance, has post-treatment effect, and
its  duration therapy is generally ﬁnite. However, it also has
some  disadvantages, such as requiring injection, less potent
suppression of HBV DNA, and an increase in adverse events.40
LAM had the worst QALY values in HBeAg positive and all
patients  groups. However, in both groups, LAM was  the third
most  cost-effective product. This is due to lower cost of LAM
compared  to other drugs. Of all evaluated drugs, LAM had the
lowest  cost at U$ 117.
The  study was  considered robust by the constancy in their
univariate results despite changes in some parameters con-
sidered  important for the analysis (cost and effectiveness),
because in all cases, TDF was  more  cost-effective and dom-
inated  the other treatment options.
In recent years, health spending has risen and become a
problem  in developed countries and particularly in develop-
ing  countries. The causes of increases in spending are diverse
and  may  be related to the emergence of new technologies,
often more  effective but more  expensive. Moreover, with the
emergence  of new diagnostic and therapeutic strategies, life
expectancy  is rising, increasing the number of elderly and
therefore  overall spending on health. There is a continuous
struggle by health systems to maximize health gains with the
use  of available resources. Economic evaluations are critical in
determining the best allocation of resources, looking for the
most  cost-effective alternatives especially in the treatment of
chronic  diseases.
Such  use of economic evaluations has increased signif-
icantly worldwide. Several economic evaluations have been
performed  in order to compare the cost-utility of treat-
ments for chronic hepatitis B, aiming at a better allocation
of  resources in health.
In  Kanwall’s study conducted in the United States in 2005,
the  treatment strategies with ADF, LAM and IFN were  com-
pared  with no treatment. IFN was  the most cost-effective
drug among the three, both in HBeAg positive and negative
patients, and the ADF and LAM were  dominated strategies.33
Another study performed in Asia in 2008, compared LAM, ETV,
and LAM in association with ADF, in HBeAg positive patients. 1 3;1  7(4):418–426
ETV  was more  cost-effective in reducing levels of HBV DNA
and  HBeAg seroconversion.42 In Brazil, the ETV was compared
directly to LAM in a study in 2008. The study was  conducted
in  the context of the Brazilian public health system on a time
horizon  of ten years. For HBeAg positive and HBeAg negative
patients, the ETV was  more  cost-effective when compared to
LAM.43 In the United States, in 2008, Veenstra et al. evaluated
the  cost-effectiveness of treatments with PEG-IFN or LAM for
chronic hepatitis B in HBeAg negative patients. PEG-IFN- was
more  cost-effective than LAM.36 A Spanish study conducted in
2009 assessed the cost-effectiveness ratio between the drugs
ADF,  ETV, LAM, LdT, and TDF in HBeAg positive and HBeAg neg-
ative patients. TDF was  the most cost-effective drug in both
groups  (HBeAg positive and negative).44 In 2010, an economic
evaluation carried out in Lithuania, compared PEG-IFN- with
IFN-  and with LAM, for the treatment of chronic hepatitis B
in  HBeAg positive and negative patients. PEG-IFN- was  the
most  cost-effective drug among the three.45
Despite several economic evaluations already carried out
worldwide,  a comparison of costs among different countries
is  difﬁcult to achieve, since every nation has its own unique tax
burden and economic structure. Data from studies conducted
in  other countries generally cannot be extrapolated.
The incorporation of new technologies must be done
appropriately in health care in order to generate the best
impact  on the health of the population. It is important to
note  that cost-utility assessments provided by different health
technologies  serve to guide the manager and the clinician in
his  choice of alternatives. Health decisions cannot be treated
as  part of the exact sciences, and they must be rational and
supported  in the data, but cannot be as extreme as to eliminate
alternatives based solely on numerical data.
Limitations
The modeling for economic evaluations can bring limitations
because values are extrapolated based on ﬁndings in the litera-
ture  and created scenarios. Sensitivity analyses are performed
to  try to minimize possible variations in the model. However,
some  limitations should be considered.
First, the results of clinical outcomes of this study were
derived  from clinical studies from the last ten years. Clinical
trials  evaluate the efﬁcacy of therapies, and not effectiveness,
which reﬂect the clinical practice in use. The course of
chronic  HBV infection is dynamic, which could be modiﬁed
signiﬁcantly with anti-HBV agents but it is still dynamic. We
used  data extracted from systematic review that only had
limited  therapy interval and limited follow-up duration to
estimate  the long-term cost-effectiveness of drug therapy.
Moreover, there might be signiﬁcant differences in the HBeAg
seroconversion rate and viral resistant rate in the 1st and
2nd  year of treatment. Thus, one year data could lead to
signiﬁcant bias. However, these data were used because there
are  no clinical studies available for all these drugs with more
than  one year duration.
The  population involved in clinical trials is heterogeneous,
and the responses to treatments may  be different in our pop-
ulation.  Also, different genotypes were found in the included
studies,  which are not necessarily the same genotypes found
in  the Brazilian population.
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Another important limitation of the study is that in the
arkov  model, it was  assumed that the patient cannot be
n  two health states at the same time. This assumption dif-
ers  from reality because patients could, for example, have
ecompensated cirrhosis and hepatocellular carcinoma at the
ame  time, and still experience a serious adverse event. How-
ver,  the model precludes the representation of this type
f  a situation because the clinical trials report the data
eparately.
TDF  was  found to be the drug with the best cost-utility ratio
or  the three groups of patients. However, this information is
scertained only from two studies, as described in the article
y  Marcellin et al.11 A larger number of studies may  provide a
ore  reliable result. New clinical studies of TDF would, there-
ore,  increase the robustness of this result.
The results of this study establish the cost-utility of drugs
vailable in Brazil used to treat chronic hepatitis B. Under-
tanding this relationship is crucial for health professionals;
t  bolsters the decision-making process. It is essential for doc-
ors  to be aware of the cost-utility ratios of each drug. However,
ach  patient responds to therapy in different ways  and should
e  evaluated individually.
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